Avalyn Pharma Inc. (NASDAQ:AVLN – Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $33.32 and last traded at $32.73, with a volume of 171345 shares. The stock had previously closed at $31.00.
Wall Street Analysts Forecast Growth
Several equities analysts have weighed in on the company. Morgan Stanley initiated coverage on Avalyn Pharma in a research report on Tuesday, May 26th. They issued an “overweight” rating and a $53.00 target price for the company. Jefferies Financial Group initiated coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They issued a “buy” rating and a $52.00 price objective for the company. Evercore initiated coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price objective for the company. Wall Street Zen raised shares of Avalyn Pharma to a “hold” rating in a research note on Saturday, May 9th. Finally, Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $59.00.
View Our Latest Analysis on Avalyn Pharma
Avalyn Pharma Trading Down 3.9%
Avalyn Pharma (NASDAQ:AVLN – Get Free Report) last announced its quarterly earnings data on Wednesday, June 3rd. The company reported ($21.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($16.38) by ($5.45).
Insider Buying and Selling
In other news, major shareholder Sr One Capital Management, Llc purchased 555,555 shares of the stock in a transaction on Friday, May 1st. The stock was bought at an average price of $18.00 per share, for a total transaction of $9,999,990.00. Following the acquisition, the insider directly owned 2,186,562 shares of the company’s stock, valued at approximately $39,358,116. The trade was a 34.06% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jill Carroll acquired 277,778 shares of the company’s stock in a transaction on Friday, May 1st. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $5,000,004.00. Following the completion of the transaction, the director owned 2,186,562 shares in the company, valued at approximately $39,358,116. The trade was a 14.55% increase in their position. The SEC filing for this purchase provides additional information.
Avalyn Pharma Company Profile
We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.
Featured Stories
- Five stocks we like better than Avalyn Pharma
- Agility Robotics’ SPAC Deal Opens a Rare Door Into Humanoid AI
- SMRs Spark a Chain Reaction for Nano Nuclear
- Netflix Stock Is Near 2021 Levels, and Bulls See 4 Reasons to Care
- Tesla Stock Surges 15% as FSD Update Backs Its Autonomy Thesis
Receive News & Ratings for Avalyn Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalyn Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
